Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Pancreatic Neoplasms 11Breast Neoplasms 8Prostatic Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Melanoma 5COVID-19 4Multiple Myeloma 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Leukemia 2Glioblastoma 2Cholangiocarcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Urologic Diseases 1Untreated Resectable Pancreatic Adenocarcinoma 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Multiple Myeloma × Hydroxychloroquine × Clear all
NCT04163107 2022-03-18

MYELOMA-HCQ

Norwegian University of Science and Technology

Phase 1 Completed
19 enrolled
Plasma cell

Multiple Myeloma

NCT00568880 2020-02-07

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01689987 2017-09-07

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
18 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡